Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 16/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.53 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336563 | 0.92 | DHODH (0.64) | DHODHGAAL3MBTL1NR4A2NR4A1 | |
| SCHEMBL1337478 | 0.91 | DHODH (0.71) | DHODHGAAL3MBTL1NR4A2NR4A1 | |
| SCHEMBL1336975 | 0.88 | DHODH (0.79) | DHODHGAAL3MBTL1NR4A2RXRA | |
| SCHEMBL1336884 | 0.88 | DHODH (0.78) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL1337552 | 0.84 | RXRA (0.61) | DHODHGAANR1H4RXRARXRB | |
| SCHEMBL1337908 | 0.84 | DHODH (0.58) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL1337733 | 0.83 | DHODH (0.69) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL1335669 | 0.83 | DHODH (0.69) | DHODHGAAL3MBTL1RXRARXRB | |
| SCHEMBL254247 | 0.82 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL15928753 | 0.82 | ALDH1A1 (0.58) | DHODHGAAL3MBTL1NR4A2NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | claimed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | claimed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | claimed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | claimed |
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| EP-2566847-A1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | Icozen Therapeutics Pvt. Ltd. (IN) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138665-A1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885GAA 246/4885L3MBTL1 4504/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885GAA 246/4885L3MBTL1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.